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Transmission Disequilibrium
of Small CNVs in Simplex Autism
Niklas Krumm,1 Brian J. O’Roak,1 Emre Karakoc,1 Kiana Mohajeri,1 Ben Nelson,1 Laura Vives,1
Sebastien Jacquemont,2 Jeff Munson,3 Raphe Bernier,3 and Evan E. Eichler1,4,*
We searched for disruptive, genic rare copy-number variants (CNVs) among 411 families affected by sporadic autism spectrum disorder
(ASD) from the Simons Simplex Collection by using available exome sequence data and CoNIFER (Copy Number Inference from Exome
Reads). Compared to high-density SNP microarrays, our approach yielded ~23 more smaller genic rare CNVs. We found that affected
probands inherited more CNVs than did their siblings (453 versus 394, p ¼ 0.004; odds ratio [OR] ¼ 1.19) and that the probands’
CNVs affectedmore genes (921 versus 726, p¼ 0.02; OR¼ 1.30). These smaller CNVs (median size 18 kb) were transmitted preferentially
from the mother (136 maternal versus 100 paternal, p ¼ 0.02), although this bias occurred irrespective of affected status. The excess
burden of inherited CNVs among probands was driven primarily by sibling pairs with discordant social-behavior phenotypes (p <
0.0002, measured by Social Responsiveness Scale [SRS] score), which contrasts with families where the phenotypes were more closely
matched or less extreme (p > 0.5). Finally, we found enrichment of brain-expressed genes unique to probands, especially in the SRS-
discordant group (p ¼ 0.0035). In a combined model, our inherited CNVs, de novo CNVs, and de novo single-nucleotide variants all
independently contributed to the risk of autism (p < 0.05). Taken together, these results suggest that small transmitted rare CNVs
play a role in the etiology of simplex autism. Importantly, the small size of these variants aids in the identification of specific genes
as additional risk factors associated with ASD.Introduction
Discovering the mutations and the genes responsible for
autism spectrum disorder (ASD) requires an assessment
of the full spectrum of genetic variation, including both
de novo and inherited events, within families. There is
compelling evidence that a diverse range of de novo
mutations, including copy-number variants (CNVs),1–5
single-nucleotide variants (SNVs), and insertions and
deletions (indels),6–10 play an important role. However,
all together, de novo variation does not fully explain the
genetic etiology of ASD: only ~8% of probands carry a
de novo CNV, and ~10%–20% carry a pathogenic de
novo SNV or indel. Many of these mutations most likely
play a pathogenic role in the development of ASD, espe-
cially in the context of sporadic (or ‘‘simplex’’) ASD. How-
ever, the heritability of ASD is estimated to be between
50% and 90%11–13—much higher than the explained
fraction of disease to date—suggesting that additional
genetic factors contribute to the etiology of ASD.
The prevalence of rare CNVs smaller than 50 kb has been
underestimated in previous surveys using oligonucleotide
microarrays,1,2 and their role in ASD has not been exten-
sively explored (but see Prasad et al.14 for an analysis of
small CNVs in a case-control ASD cohort). Such patho-
genic events could in principle provide as much specificity
as exonic de novo mutations with respect to genes and
informative protein networks. Several recent methods
based on exome sequencing read-depth data, such as
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The Americemployed in this work, have enabled the discovery of small
genic CNVs previously missed by microarray.15 In this
study, we tested the hypothesis that small genic inherited
CNVs also contribute to the genetic etiology of sporadic
autism. Several lines of evidence—including increased
prevalence of the broader autism phenotype (BAP) in par-
ents of affected children,16,17 trends for higher burden
of extremely rare singly transmitted CNVs in simplex
families,1 and enrichment of large CNVs in cases versus
unrelated controls5—are potentially supportive of this hy-
pothesis. In contrast, other previous studies that examined
inherited CNVs in ASD found no significant excess of
inherited burden in probands with ASD, although these
studies were mainly designed to detect de novo CNVs.2
We investigated families in which both affected and
unaffected siblings had been exome sequenced, and here
we present evidence of transmission disequilibrium for
smaller CNVs (median size ~18 kb). By leveraging normal-
ized read depth fromwhole-exome sequence data, we have
added nearly 2-fold inherited, small, genic CNVs to the
body of known variants in these samples. Finally, we pre-
sent a model that integrates both rare SNVs and CNVs to
more fully explain the genetic architecture of ASD.Material and Methods
CNV Detection from Exome Sequence Data
We analyzed exome sequence data from families ascertained as
part of the Simons Simplex Collection (SSC).18 Underlying FASTQ
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(consisting of a proband, an unaffected sibling, a mother, and a
father),6–8 and we generated sequence data for an additional 19
unaffected siblings from published trios.10 The data set included
sequence data (median coverage > 503) from 411 families in
which a quad had been sequenced for a total of 1,644 samples
(see Table S1 and S2, available online, for details). Sequence reads
were split into 36-mers and were mapped with the mrsFAST align-
ment program19 to the Nimblegen EZ-SeqCap v.2 targets
(including 300 bp around each target and allowing two mis-
matches per 36-mer). We used CoNIFER15 to calculate exon-level
coverage and removed systematic bias between samples and
targets. Using a custom pipeline (Figure S1), we (1) segmented
our CoNIFER SVD-ZRPKM values by using the DNACopy algo-
rithm,20 (2)minimized false negatives by a quad-based genotyping
method, (3) clustered CNVs into overlapping CNV regions
(CNVRs), and (4) removed CNVs found in duplicated or repetitive
genomic space.We limited our final call set to inherited CNVs (i.e.,
transmitted CNVs) that were present in ten or fewer families
(or approximately 1% population frequency), and we excluded
CNVs that primarily fell within duplicated or highly polymorphic
regions of the genome. We considered a CNV ‘‘rare’’ if it occurred
in ten or fewer families and a CNV ‘‘private’’ if it was observed only
in one family. Lastly, we did not include CNVs on the X chromo-
some in any analysis, and all de novo CNVs were excluded from
burden analyses except where noted. Throughout this paper, we
define ‘‘CNV burden’’ as the number of rare CNVs per individual.
This study was approved by the institutional review board of the
University of Washington.Array Comparative Genomic Hybridization
We designed a customized comparative genomic hybridization
(CGH) microarray (Agilent SurePrint G3 4x180K CGHmicroarray;
probe density ranged from 1/125 bp to 1/5 kb depending on the
size of the event to be validated) and selected 161 CNVs from a
subset of 80 samples, stratified by affected status (36 probands
and 44 siblings) and by data set (26 from Iossifov et al.,6 22 from
O’Roak et al.,7 32 from Sanders et al.8 [Tables S1 and S5]). The min-
imum deletion and duplication thresholds for validation were
determined by receiver operating characteristic (ROC) curve anal-
ysis of known positive- and negative-control CNVs (Figure S3).Phenotypic Measures and Models
The Social Responsiveness Scale (SRS) was used as a quantitative
measure of social deficits.21 We had complete phenotype informa-
tion based on data from the SSC (SRS scores for both probands and
siblings and full-scale IQs [FSIQs] for probands) for 389 families in
this study (Table S7). The probands in this study had a median SRS
t-score of 82, significantly higher (i.e., indicating a more severe
phenotype) than the median SRS score of our unaffected siblings
(45; p < 0.00001, two-tailed paired t test). We defined mild, mod-
erate, and severely affected individuals on the basis of published
thresholds.21Expression Analysis
Gene-expression data were from the Human U133A/GNF1H Gene
Atlas (Gene Expression Omnibus accession number GSE1133),
comprising 79 human tissues, including 18 nervous system tis-
sues.22 Expression values were averaged across multiple probes
when available.We defined a gene to be expressed in a given tissue
if it ranked in the top 5% of all genes for that tissue. To measure
enrichment, we compared the fraction of genes unique to either596 The American Journal of Human Genetics 93, 595–606, Octobersiblings or probands expressed in each tissue and calculated empir-
ical p values by shuffling proband and sibling labels 20,000 times
and recomputing tissue-level expression enrichment. We used the
false discovery rate (FDR) method to correct for 79 tests (i.e., for
tissues) and assessed statistical significance at q < 0.05.
Combined Mutation Model
We generated a list of truncating de novo SNVs (nonsense, frame-
shift, or splice mutations) discovered in our 411 quads from pub-
lished lists.6–8,10 Both de novo and inherited CNV burden was
derived from this work (Tables S3 and S4).We used a logistic regres-
sion model, which transforms the binary outcome (i.e., affected
versus unaffected) such that linear predictors can be used. The
model shown in Figure 5 is summarized as follows:
logit½Pðaffected ¼ 1Þ  interceptþ ðde novo CNV burdenÞ
3 ðinherited CNV burdenÞ3 ðde novo SNV burdenÞ:
Results
Samples and CNV Discovery
We discovered a total of 847 transmitted, exonic, rare,
autosomal CNVs (Table 1), including 453 transmitted to
probands and 394 transmitted to unaffected siblings. Over-
all, the median estimated CNV size was 18.1 kb (range ¼
150 bp to 5.18 Mb or 2–320 exons). The median size of in-
herited CNVswas slightly larger in probands (19.4 kb) than
in unaffected siblings (16.6 kb), but this difference was not
statistically significant. As expected, duplications outnum-
bered deletions (519 versus 328, p < 1 3 1010, binomial
two-tailed test), and duplications were significantly larger
than deletions (two-sided Mann-Whitney U test, p < 1 3
1016). The excess of duplications depended upon the
size of the event. For example, rare CNVs involving 20 or
more exons were overwhelmingly duplications (139 dupli-
cations versus 25 deletions), whereas small events were not
significantly different (73 duplications and 93 deletions for
2-exon CNVs). This difference was observed irrespective of
disease status (Figure S4).
Validation Using SNP Microarray and Targeted
Array CGH
We assessed the specificity of our call set by comparing our
larger calls to Illlumina 1M/Duo SNP microarrary data and
then selecting a subset of 80 samples for validation of
smaller CNVs by array CGH validation. These 80 samples
carried a total of 161 exome-based CNV calls, of which
69 (43%) were confirmed by SNP microarray (Figure 1A).
Using a customized microarray design (Material and
Methods), we were able to test 86 of the 92 remaining calls
and confirmed an additional 65 events (nearly a 2-fold
increased yield of CNVs) (Table S5). Of the 27 events not
validated by array CGH, 14 (or 9% of all 161 calls) were
found to be specifically part of processed pseudogenes
(i.e., retrotranscribed mRNA), which masquerade as dupli-
cations in exome-based discovery of CNVs, indicating that
these events—although not genomic CNVs—were in fact3, 2013
Table 1. Summary of Transmitted CNVs in 411 ASD Quads
Category CNVs Dups Dels Median Size (Estimate) Percentage of Samples CNVs > 500 kb CNVRs
All proband CNVs 453 277 176 19.4 kb 64% 21 390
All sibling CNVs 394 242 152 16.6 kb 60% 16 345
Father/ both 199 130 69 16.7 kb 41% 7 94
Father/ proband only 100 67 33 25.0 kb 19% 7 93
Father/ sibling only 82 52 30 15.4 kb 18% 2 80
Mother/ both 233 127 106 15.0 kb 48% 10 118
Mother/ proband only 136 82 54 24.9 kb 26% 5 128
Mother/ sibling only 97 61 36 21.7 kb 21% 6 94
Either parent/ proband
only
236 149 87 25.0 kb 39% 12 211
Either parent/ sibling
only
179 113 66 19.3 kb 36% 8 168
Mother/ either
offspring
466 270 196 17.8 kb 86% 21 313
Father/ either offspring 381 249 132 18.6 kb 72% 16 252
Totals 847 519 328 18.1 kb 62% 37 525
The following abbreviations are used: dups, duplications; and dels, deletions.true duplications of these genes or exons. Thus, we esti-
mated an overall false-positive rate (FPR) of 4%–8%
(7/155 tested or 13/161 in total; Figure 1A), depending
on the number of probes (or exons) in each call: for calls
with fewer than ten exons, the FPR was ~7% (6/104),
whereas only one call with ten or more exons did not
validate (1/51 [2%]). There was no difference in the FPR
between probands and siblings (3/68 [4.2%] for probands
versus 4/80 [4.5%] for siblings; Table S6).
We also assessed the sensitivity (or false-negative rate
[FNR]) of our calls versus the previously identified CNVs
from SNP microarray data. We found that our pipeline
identified 72% (FNR of 0.28) of all known CNVs intersect-
ing at least two exons and supported by ten SNP microar-
ray probes. False-negative CNVs corresponded to samples
with reduced mapped sequence coverage (Figure S2). For
example, the Iossivof data set6 had an approximately
2-fold higher FNR, most likely due to the lower overall
sequence coverage in these exomes (a known factor in
exome-based CNV discovery14,15), and the FNR for calls
affecting only two exons was significantly higher than
for those with three or more exons (Table S6). We found
no differences in the mapped coverage, estimated FPRs,
or estimated FNRs among siblings and probands (p > 0.3,
Fisher’s two-sided exact test and Table S6).
Increased Inherited CNV Burden among Autism
Probands
We compared the burden of inherited CNVs in the 411
probands and their siblings in terms of the total number
of CNVs and the total number of genes ‘‘hit.’’ We found
that probands inherited more CNVs than did their siblingsThe Americ(453 versus 394; Figure 2A) and that the probands’ CNVs
harbored more genes (921 versus 726; Figure 2B). These
comparisons were significant when a paired t test was
used for proband-sibling pairs (p ¼ 0.02 for genes and
p ¼ 0.004 for CNVs, two-tailed paired t test) and when
the summed values for probands and siblings were
compared in aggregate (p < 1 3 106 for genes and p ¼
0.046 for CNVs, binomial two-tailed test). In order to
ensure that these results were not driven by a few outlier
families, we bootstrapped our data and calculated the con-
fidence intervals (CIs) for the proband-to-sibling burden
(Figure S5). We found a median burden increase of 1.19
(95% CI ¼ 1.09–1.29) for CNVs and a burden increase of
1.30 (95% CI ¼ 1.10–1.52) for genes across 10,000 boot-
strap replicates, thereby rejecting the null hypothesis
that the inherited CNV burden in probands is not higher
than that in their siblings (Figure S5). Proband CNV
burden was elevated over that of siblings across all size
ranges, although individual quintile bins did not indepen-
dently achieve statistical significance because of their
smaller size (Figure 2C). We found no significant enrich-
ment of burden in either the smallest or the largest CNVs
(by chi-square test: c2 ¼ 1.18, p ¼ 0.95, 5 degrees of
freedom [df]), suggesting that the burden was not exclu-
sively the result of either small or large CNVs.
Previous work has indicated that private or ultra-rare
CNVs might be more likely to be pathogenic than simply
‘‘rare’’ (e.g., <1% frequency) CNVs.1 We therefore exam-
ined whether the inherited burden in probands was due
to private CNVs in a small subset of the 411 families. We
examined 271 private CNVs in probands and 245 private
CNVs in siblings but found no enrichment of privatean Journal of Human Genetics 93, 595–606, October 3, 2013 597
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Figure 1. Discovery and Validation of CNVs with the Use of Exomes
(A) Fraction of CNVs previously identified via Illumina 1M SNPmicroarray (gray, ‘‘known true positives’’), the fraction of CNVs identified
and confirmed by targeted array CGH in this study (green, ‘‘CNVs identified in this study’’), confirmed processed pseudogenes (hatched
green), and the overall FPR for unconfirmed CNVs (gray).
(B) The majority (73% [152/207]) of all calls (green) identified in this study with the use of exomes were smaller than 20 kb.
(C–D and F) Three examples of CNVs in this study. Top: CoNIFER output and normalized coverage at each exon. Middle: targeted array
CGH at CNV locus; the threshold for deletion or duplication (dotted red line) was determined by ROC-curve analysis of known CNVs
(Supplemental Data). Bottom: Illumina 1M SNP microarray data for locus shows poor probe coverage (C and D only).
(E) Exome-based CNV discovery affords high exon-level specificity, as indicated by duplication of NETO1 exons (y, CoNIFER call).
Previous work (Sanders et al.2) discovered this CNV (*), but the (incorrect) breakpoints did not extend into NETO1.burden when compared to rare CNVs (p ¼ 0.74, Fisher’s
exact test; Figure S6A), nor did we find enrichment of the
number of affected genes (p ¼ 0.46, fisher’s exact test;
Figure S6B). (Note: the burdenwas in fact slightly increased
when all rare events were considered.) We searched for
additional factors that could underlie the proband-sibling
burden differential. We found no significant differences
in CNV burden dependent on the sex of the proband or
sibling, the concordance of their sexes, or the birth order
of the proband and sibling (p > 0.5, Fisher’s exact test;
Table S8). However, we note that the highest overall CNV
burden was found in families with one affected proband
and at least three unaffected siblings. In fact, there was a
linear increase in burden between probands and siblings
across increasing family size, culminating in a 1.38-fold598 The American Journal of Human Genetics 93, 595–606, Octoberhigher burden of CNVs in probands with three or more
unaffected siblings.
Finally, we analyzed our data set for parent-of-origin
effects and found a greater number of maternally trans-
mitted CNVs (136 maternal versus 100 paternal, binomial
two-tailed p value ¼ 0.02), but this effect was not signifi-
cantly enriched in probands versus siblings (Fisher’s exact
test odds ratio [OR] ¼ 1.14, two-tailed p ¼ 0.49). Nonethe-
less, when we considered a null hypothesis in which a
given transmitted CNVwas equally likely to be transmitted
to the proband only, the sibling only, or both (each with 1/
3 probability), we found strong evidence that CNVs were
not transmitted in equal fashion (Table 1; chi-square test
with equal expected proportions: c2 ¼ 16.4, p ¼ 0.0058,
5 df) and that CNVs transmitted from the mother to the3, 2013
Figure 2. Increased Inherited CNV
Burden in ASD Probands for Large and
Small CNVs
(A) Total number of rare (observed in fewer
than ten families) inherited CNVs (at least
two exons) for 411 ASD probands (Pro)
and their unaffected siblings (Sib).
(B) Total number of affected genes in rare
inherited CNVs. p values refer to two-
tailed paired t tests between proband and
sibling counts.
(C) Burden of inherited CNVs across six
size categories.proband only were significantly more common than other
transmissions.
Correlation between CNV Burden and the ASD
Phenotype
We used phenotype data from the SSC to assess whether
the increased inherited CNV burden would segregate
with markers of ASD phenotypic severity. First, we utilized
the SRS, a standardized parent- or teacher-completed ques-
tionnaire that measures the severity of autism symptoms
in social settings (but is not a diagnostic indicator of ASD
and was not used in the ascertainment of the SSC). We par-
titioned our 411 families into two groups on the basis of
the SRS t-score: we defined (1) ‘‘SRS-discordant quads’’ as
those where the proband was severely affected (SRS t >
75) and the sibling was mildly affected (SRS t < 60) and
(2) ‘‘SRS-concordant quads’’ as all others (Figure S7). The
concordant group encompassed a range of moderately
affected probands and some moderately affected siblings
(Figure S7). There were a total of 276 SRS-discordant pro-
band-sibling pairs and 115 concordant pairs according
to this definition. We found a striking split between the
discordant and concordant proband-sibling pairs: the
increased CNV and gene burden was almost completely
driven by the discordant pairs (p < 0.0002 for CNVs, p <
0.02 for genes, two-tailed paired t test [Figure 3A]), and
there was virtually no difference at a group or family level
for SRS-concordant pairs overall (1.043, p > 0.5). More-
over, the burden ratio between probands and siblings
was increased in the discordant group (1.273 for CNVs
and 1.413 for genes) over the ratio for the full set of 411
quads. Finally, we found that offspring (probands and sib-
lings) with SRS scores R 60 (‘‘moderate’’ and ‘‘severe’’
range) had higher CNV burden than did all offspring
with SRS scores < 60 (361 CNVs in 390 mildly affected
offspring [1.12] versus 436 CNVs in 388 moderately orThe American Journal of Human Geseverely affected offspring [0.92];
two-tailed independent t test p <
0.0094). There was no statistically sig-
nificant difference in burden between
probands and siblings within each
group (i.e., SRS < 60 or R 60); how-
ever, the relatively low number of‘‘affected’’ siblings and ‘‘unaffected’’ probands hampered
these comparisons.
Next, we considered whether the FSIQ of the probands
was affected by inherited CNVs. Because FSIQ scores were
only available for probands (Table S7), we grouped quads
into three groups: FSIQ % 70 (‘‘low,’’ consistent with a
diagnosis of intellectual disability), between 71 and 85
(‘‘intermediate’’), or greater than 85 (‘‘high’’). The CNV
burden was significantly greater for probands in the
‘‘low’’ and ‘‘intermediate’’ proband FSIQ bins (1.253–
1.273 burden, Table 2). Probands with ‘‘high’’ FSIQ did
not show statistically significant enrichment over siblings,
although a trend was still apparent (1.113, Table 2). When
we examined the effect of SRS and FSIQ together (Table 2,
Table S8, and Figure S8), we found that the burden differ-
ential was strongest for the most severely affected pro-
bands (those with FSIQ % 85 and part of SRS-discordant
quads); it reached 1.323–1.403 for CNVs (p ¼ 0.004).
However, there was no significant burden between pro-
bands and siblings in SRS-concordant quads, even with
‘‘low’’ FSIQ probands (0.83–1.093, p > 0.5; Table 2), indi-
cating that the inherited burden might be most closely
aligned with the SRS score rather than FSIQ (however, we
caution that there were only 22 quads total in this group).
Enrichment of Brain-Expressed Genes in Inherited
CNVs
We observed a trend in which more of the proband-only
genes were highly expressed in brain-related tissues
(19/317 [6%] for proband only versus 6/224 [2.7%] for sib-
ling only; Table S8; see Material and Methods). The effect
became most pronounced when we considered SRS-discor-
dant quads (15/256 [5.9%] genes in probands and 2/170
[1.2%] genes in siblings, p ¼ 0.007) (Figure 4). When we
considered all genes highly expressed in at least one
brain-related tissue, we found that significantly morenetics 93, 595–606, October 3, 2013 599
Figure 3. Inherited CNV Burden Corre-
lates with SRS Phenotype
(A) The SRS measures autism features in
social settings via parent report on 65
items. We classified proband-sibling pairs
with severely affected probands but mildly
or unaffected siblings as SRS-discordant
quads (276 quads) and all other quads as
SRS-concordant quads (115 quads). Strik-
ingly, the SRS-discordant quads fully reca-
pitulated the inherited CNV transmission
bias, whereas the SRS-concordant quads
did not show a differential burden.
(B) CNV burden was independent of FSIQ,
and probands with either low FSIQ (%70)
or high FSIQ had more CNVs than did
their siblings. p values refer to two-
tailed paired t tests between probands
and siblings.probands than siblings had a CNV (57/411 [13.9%] for pro-
bands versus 33/411 [8.0%] for siblings; OR ¼ 1.85, p ¼
0.009, Fisher’s exact test). These results suggest that a frac-
tion of proband-specific genes were expressed in the ner-
vous system tissues and that this fraction was higher in
proband-only genes than in sibling-only genes. Although
we caution that expression does not definitively imply
pathogenicity, many of these genes and their biological
pathways might be of interest for further study, both
for these particular individuals and for ASD genetics in
general.
We compared the genes detected in the CNVs in this
study to a set of 1,560 genes that were previously observed
in ASD, intellectual disability, or schizophrenia (Table S10Table 2. Summary of IQ and SRS Burden
Proband
FSIQ
Proband
CNVs
Sibling
CNVs Ratio
Two-Tailed t Test:
Probands versus
Siblings
All Quads
%70 157 126 1.25 p ¼ 0.014
71–85 89 70 1.27 p ¼ 0.029
R86 184 166 1.11 NS
SRS-Discordant Quads (Proband SRS < 60 and Sibling SRS > 75)
%70 138 104 1.32 p ¼ 0.004
71–85 62 44 1.40 p ¼ 0.012
R86 113 101 1.12 NS
SRS-Concordant Quads
%70 19 22 0.86 NS
71–85 27 26 1.04 NS
R86 71 65 1.09 NS
p values represent two-tailed paired t tests between probands and siblings in
each group. The following abbreviation is used: NS, nonsignificant.
600 The American Journal of Human Genetics 93, 595–606, Octoberand Figure S10). Among SRS-discordant quads, we found
significant enrichment of autism genes among proband
CNVs compared to those of unaffected siblings (66 versus
35 genes, p ¼ 0.006 two tailed paired t test; Table S8). In
contrast, there was no enrichment among SRS-concordant
proband-sibling pairs for previously observed genes (in
fact, siblings had more genes: 17 versus 24, p ¼ 0.069).
Overall, 16% (44/276) of probands in the SRS-discordant
group had a CNV in a previously observed gene, whereas
only 10% (12/115) of probands in the concordant group
had such an event. Intersecting the brain-expressed genes
and previously observed disease genes, we found that 13
genes, corresponding to 1.7% of all proband genes and
only two genes (0.3%) in siblings, matched both criteria
(Figure S10). The 13 convergent proband-only genes were
found exclusively in SRS-discordant families, indicating
that these genes might be associated with more severe
phenotypes (Table S11).Discussion
In this study, we found an enrichment of inherited CNVs
in sporadic cases versus their unaffected siblings, indi-
cating a significant CNV transmission bias for autism.
The targeted nature of exome sequencing enabled us to
explore a smaller CNV landscape largely inaccessible by
high-density SNP microarray data.1,2,5 We estimate that
the use of exome data increased our power to detect
gene-disruptive CNVs smaller than 20 kb by ~2.25-fold.
These CNVs provide potential insight into the pathophys-
iology of inherited CNVs in sporadic autism. We found
that the CNV burden was more strongly correlated with
measures of ASD phenotypes (such as the SRS score) than
with IQ; for proband-sibling pairs with concordant SRS
scores, IQ was not dependent on the probands’ CNV
burden. Genes already associated with autism and/or high-
ly expressed in the brain were more likely to be disrupted.3, 2013
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Figure 4. Genes in Proband-Only CNVs from SRS-Discordant Quads Are More Likely Brain-Expressed Genes
We defined a gene to be expressed in a tissue if it ranked in the top 5% of all genes in that tissue and calculated the fold enrichment of
proband and sibling genes expressed in each tissue. The tissues with the strongest proband enrichment were part of brain structures
(black bars), as was the computed average of expression across 18 brain regions (‘‘brain average’’). However, the particular brain tissues
with the strongest apparent enrichment should not be considered as independently enriched, given that expression values for individual
genes between brain regions are highly correlated. Asterisks indicate a FDR-corrected p value< 0.05. See Figure S9 for results from all 411
quads.Private CNVs (seen once) were no more likely than simply
rare variants (seen fewer than ten times in our families) to
be found in probands. Burden was consistent across all
sizes of CNVs, and we did not find any enrichment of
either small or large events. Mothers were significantly
more likely than fathers to be carriers of transmitted
CNVs, irrespective of the disease status of the child, consis-
tent with our recent finding that ‘‘secondary’’ CNVs are
transmitted frommothers to children with developmental
delay and multiple CNVs.23 We also noted that the trans-
mission bias became more significant in probands from
ASD-affected families with many siblings than in ASD-
affected families with fewer individuals. Although this
observation is inconsistent with the assumption that pro-
bands in larger families with many unaffected siblings
are more likely to have an underlying sporadic genetic eti-
ology, it most likely reflects an ascertainment in selecting
the ‘‘least affected’’ sibling in a large family as the ‘‘desig-
nated sibling’’ for the purposes of forming a quad.8 This
suggests that a significant fraction of the underlying
genetic etiology in the SSC might be inherited, a notion
that has been examined previously.17
Our study benefited from the quad-based design of the
SSC,18 which provided a robust genetic control for each
ASD proband, as well as the detailed phenotypic informa-
tion available, which sharpened the contrasts between
severely affected and less affected probands and their sib-
lings, some of which showed subtle signs of the BAP.17
Most of our observations were strengthened or restricted
to SRS-discordant quads, where the proband was severely
affected in terms of the SRS scale but the sibling was unaf-
fected. Approximately 67% (276/411) of the quads in thisThe Americstudy were categorized as SRS discordant, and these quads
explained virtually the entire CNV burden, encompassed
the majority of brain-expressed genes, and strengthened
the association with previously implicated disease genes.
This effect might have been driven by inherent ambiguity
in the simplex and multiplex classification scheme—a
scheme that is not truly binary but rather a continuous
probability based on the number of unaffected siblings in
the family (the more unaffected siblings, the greater the
likelihood that the family is simplex). In essence, by only
concentrating on the SRS-discordant quads, we have
focused our study on a more severe proband phenotype
but also a truly ‘‘simplex’’ genetic etiology (as opposed to
an environmental and/or stochastic one), thus enhancing
the observed transmission disequilibrium of CNVs.
Our results should be viewed carefully in the context
of previous studies. Notably, two recent studies1,2 failed
to find statistically significant enrichment of inherited
CNVs in sporadic autism probands compared to their
siblings. These studies, which also analyzed families
from the SSC, used high-density microarray platforms to
discover CNVs in a genome-wide fashion. It is possible
that the increased sensitivity of our exome-based method
for genic events— which are most strongly implicated by
studies of both de novo CNVs and de novo SNVs—revealed
the difference in burden between probands and siblings.
Additionally, our study found that the differential burden
was dependent on the SRS score and not IQ, a factor which
has not been previously examined in the context of ASD
and CNVs. In contrast, our results are in good agreement
with those of the case-control study by Pinto and col-
leagues,5 who found an overall case-control ratio of 1.19an Journal of Human Genetics 93, 595–606, October 3, 2013 601
Table 3. Selected Inherited CNVs
Sample
Chromosomal
Position (UCSC
Genome
Browser hg19)
Size
(kb) State
No. of
Exons
Frequency
in 411
Quads
Genes in Transmitted
CNVs (MIM Numbers)
Summary of De
Novo Mutations
in Proband
SRS (Proband,
Sibling, Delta)
Proband
IQ
12647.p1 chr1: 32,084,793–
32,110,465
25.7 dup 12 2 HCRTR1a (602392), PEF1
(610033)
- 88, 40, 48 72
11872.p1 chr1: 65,730,593–
65,831,879
101.3 dup 4 1 DNAJC6a (608375) KATNAL2 (SS) 88, 49, 39 62
12719.p1 chr1: 146,715,494–
146,767,190
51.7 del 23 1 CHD1Lb (613039) - 90, 48, 42 46
12997.p1 chr2: 230,632,269–
230,724,290
92 dup 39 1 TRIP12c (604506) - 81, 40, 41 97
12394.p1 chr2: 241,538,067–
241,709,123
171.1 dup 42 3 KIF1Aa,b (601255), GPR35
(602646), AQP12B, AQP12A
(609789), CAPN10 (605286)
- 77, 36, 41 88
12534.p1 chr3: 12,940,888–
12,978,197
37.3 del 13 2 IQSEC1a (610166) - 90, 42, 48 81
13099.p1 chr3: 97,486,951–
97,634,880
147.9 del 19 1 ARL6b (608845) - 86, 38, 48 92
12645.p1 chr4: 818,279–845,
762
27.5 dup 5 1 CPLX1a,b (605032), GAKb
(602052)
ANK2 (NS) 90, 36, 54 86
11773.p1 chr4: 2,641,461–
2,835,561
194.1 dup 34 1 TNIP2b (610669), FAM193A,
SH3BP2b (602104)
- 90, 42, 48 43
11066.p1 chr4: 41,258,993–
41,259,143
150 bp dup 2 3 UCHL1a,b (191342) - 82, 37, 45 88
13385.p1 chr4: 169,083,678–
169,086,477
2.8 del 3 1 ANXA10a (608008) - 90, 52, 38 16
13293.p1 chr5: 619,104–644,
540
25.4 dup 9 2 CEP72a - 90, 41, 49 83
12758.p1 chr6: 24,454,242–24,
523,153
68.9 dup 20 1 ALDH5A1a,b (610045),
GPLD1b (602515)
- 80, 40, 40 74
11551.p1 chr6: 88,315,634–88,
318,947
3.3 del 3 1 ORC3a (604972) - 90, 39, 51 98
11459.p1 chr6: 88,317,390–88,
366,700
49.3 del 10 1 ORC3a (604972) - 90, 42, 48 80
13412.p1 chr7: 33,102,179–33,
185,976
83.8 dup 7 3 RP9 (607331), BBS9b
(607968), NT5C3 (606224)
- 90, 36, 54 33
11722.p1 chr7: 48,308,576–48,
416,169
107.6 del 20 1 ABCA13b (607807) - 81, 42, 39 97
11716.p1 chr8: 38,090,512–38,
117,639
27.1 del 16 1 DDHD2a (615003) - 90, 42, 48 48
13412.p1 chr8: 86,351,940–86,
575,726
223.8 dup 14 1 CA3 (114750), CA2a,b
(611492), REXO1L1
- 90, 36, 54 33
12534.p1 chr8: 145,947,028–
146,033,780
86.8 dup 18 1 ZNF251, ZNF34 (14526),
ZNF517,a RPL8 (604177)
- 90, 42, 48 81
11356.p1 chr9: 139,634,401–
139,651,044
16.6 dup 16 1 LCN6a (609379), LCN10c
(612904), LCN8a (612902)
NAPRT1 (SS) 90, 42, 48 72
13162.p1 chr10: 5,203,384–
5,260,723
57.3 del 12 1 AKR1C4a (600451),
AKR1CL1
RIMS1 (FS) 90, 36, 54 74
13843.p1 chr11: 43,772,460–
43,775,671
3.2 del 2 1 HSD17B12a (609574) - 90, 42, 48 66
11241.p1 chr12: 120,875,929–
120,884,632
8.7 dup 7 2 GATC, COX6A1a (602072),
TRIAP1 (614943)
- 90, 38, 52 76
12396.p1 chr14: 105,836,177–
105,861,009
24.8 dup 17 1 PACS2a (610423) - 90, 51, 39 99
(Continued on next page)
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Table 3. Continued
Sample
Chromosomal
Position (UCSC
Genome
Browser hg19)
Size
(kb) State
No. of
Exons
Frequency
in 411
Quads
Genes in Transmitted
CNVs (MIM Numbers)
Summary of De
Novo Mutations
in Proband
SRS (Proband,
Sibling, Delta)
Proband
IQ
11479.p1 chr15: 43,696,610–
43,701,294
4.7 dup 5 1 TP53BP1a (605230),
TUBGCP4c (609610)
- 79, 46, 33 133
13843.p1 chr15: 55,475,512–
55,497,903
22.4 dup 6 2 RAB27Ab (613262),
RSL24D1
- 90, 42, 48 66
12837.p1 chr15: 57,730,197–
57,754,090
23.9 dup 7 2 CGNL1c (607856) - 86, 57, 29 89
13543.p1 chr15: 91,488,121–
91,520,001
31.9 del 25 2 RCCD1, PRC1c (603484),
UNC45A (611219)
- 82, 40, 42 42
13215.p1 chr16: 15,596,178–
15,609,285
13.1 del 6 1 C16orf45a - 90, 51, 39 74
14201.p1 chr16: 68,710,287–
68,713,877
3.6 dup 5 2 CDH3c (114021) - 90, 45, 45 43
12100.p1 chr16: 70,714,696–
70,714,928
232 bp dup 2 3 MTSS1La chr16: 29,675,049–
30,199,897 (CNV)
90, 38, 52 71
12373.p1 chr16: 81,314,461–
81,396,216
81.8 dup 10 1 GANa,b (605379), BCMO1
(605748)
- 90, 52, 38 NA
12697.p1 chr18: 24,436,174–
24,628,467
192.3 dup 10 1 CHST9 (610191), AQP4a
(600308), CHST9-AS1
- 80, 46, 34 85
12869.p1 chr18: 72,229,281–
72,251,798
22.5 dup 8 1 CNDP1a (609064) - 90, 36, 54 31
11356.p1 chr18: 77,470,345–
77,891,075
420.7 dup 28 2 KCNG2a (605696), RBFA,
CTDP1b (604927), ADNP2,
TXNL4A (611595), PQLC1
NAPRT1 (SS) 90, 42, 48 72
13296.p1 chr19: 6,681,951–
6,686,913
5 dup 8 1 C3a (120700) - 87, 40, 47 30
11298.p1 chr19: 18,704,375–
18,704,917
542 bp dup 2 1 CRLF1a (604237) - 90, 37, 53 141
13815.p1 chr19: 57,835,049–
57,932,849
97.8 del 15 1 ZNF547, ZNF304 (613840),
ZNF17,a ZNF548, ZNF543
CNTNAP4 (CNV) 82, 44, 38 51
13396.p1 chr21: 19,628,825–
19,632,603
3.8 del 3 1 CHODLa (607247) - 83, 43, 40 103
13327.p1 chr21: 35,742,777–
35,899,047
156.3 dup 8 2 KCNE2a (603796), RCAN1
(602917), KCNE1 (176261),
FAM165B
- 90, 45, 45 103
The following abbreviations are used: dup, duplication; del, deletion; SS, splice site; NS, nonsense; and FS, frameshift.
aBrain expression.
bPreviously associated with disease.
cTarget of previously discovered disruptive de novo SNV.for genic CNVs and no enrichment for ‘‘ultra-rare’’ CNVs
seen only once in their cases (although this study was
largely limited to CNVs larger than 50 kb).
In contrast to previous studies focused on large CNVs,
which typically encompass dozens of genes, our study’s
sensitivity for smaller CNVs provides increased specificity
to define individual genes. The deletion or duplication of
a subset of exons can have, in principle, the same impact
on gene function as disruptive point mutations. Accord-
ingly, several genes in our brain-expressed and SRS-discor-
dant set of CNVs have been previously identified as part of
severe neurological disorders. Among these was a CNV
affecting DDHD2, which encodes an intracellular phos-
pholipase that plays an essential role in synaptic functionThe Americand which has recently been implicated in a recessive form
of complex hereditary spastic paraplegia (MIM 615033),
a syndrome characterized by early-onset intellectual
disability and spastic paraplegia.24 We did not observe
any CNVs in this gene in 2,972 control exomes. Similarly,
another proband (and 0/2,972 controls) carried an in-
herited CNV affecting only PACS2 (MIM 610423), one of
six genes in a critical region of 14q32 deletion syndrome,
characterized by intellectual disability and mild facial dys-
morphology.25 Lastly, in two families, we identified a small
(~5 kb), 2-exon deletion in ZNF396 (Figure 1C), which was
identified as a candidate gene for alopecia with mental
retardation syndrome (MIM 613930) by microsatellite
linkage analysis26 (in fact, ZNF396 was the closest genean Journal of Human Genetics 93, 595–606, October 3, 2013 603
Figure 5. A Combined Model of Inherited and De Novo Mutations Reveals Independent Risk for Both
A logistic regression model estimates the OR for each inherited CNV (blue), de novo CNV (red), or disruptive de novo SNV (gray;
nonsense and splice mutations and indels only) in probands and siblings. ORs and burden (proband-sibling ratio) given in the accom-
panying table reveal independent risk for each type ofmutation. The line width for each type ofmutation in the figure indicates whether
a bias was observed for new mutations arising on the maternal or paternal haplotypes (see also O’Roak et al.7 for SNVs and Hehir-Kwa
et al.,34 for CNVs).to the linkage peak). The frequency of this deletion in our
control set was 3/2,972 (0.1%). Although these identified
genes and CNVs might play an important role in the path-
ogenesis of ASD on the basis of their previously identified
roles in Mendelian disorders, we would like to emphasize
that their individual rarity and overall small effects prevent
them from being conclusively identified as having Mende-
lian effects.
Other genes disrupted by CNVs have functional roles in
neural function, brain development, or neurobehavioral
phenotypes in model organisms (Table 3). For example,
we identified two independent disruptions of ORC3
(MIM 604972; one shown in Figure 1D), encoding a
protein in the origin recognition complex. The complex
regulates dendritic spines and dendrite arborization in
postmitotic neurons and has been implicated in olfactory
learning and memory in Drosophila.27 Notable also was a
CNV affecting CPLX1 (MIM 605032; Figure 1F), specific
to the SNARE neuronal vesicle exocytosis pathway in neu-
rons, as well as CNVs affecting neural receptors such as
HTR3E (MIM 610123; a subunit of the ionotropic serato-
nin receptor) and NETO1 (MIM 607973; Figure 1E), a key
component of the NMDA-receptor complex and critical
for synaptic plasticity and learning in mice28 (however,
this CNV was transmitted to both probands and siblings).
Previous work has implicated the ubiquitin-processing
pathway,4 and we found a rare CNV in UCHL1 (MIM
191342), which encodes a ubiquitin-adduct-processing
enzyme and has strong and specific brain expression;
UCHL10-knockout mice show specific neurodegenerative
phenotypes,29 and recent work has shown this gene to
regulate the NCAM1 neural cell adhesion molecule (MIM
116930; Wobst et al.30). Finally, we found several inter-
esting mutations on the basis of brain expression pattern,
including (1) an inherited deletion of IQSEC1 (MIM
610166), which is strongly expressed in the prefrontal
cortex and involved in clathrin-mediated endocytosis
of AMPA receptors critical to long-term potentiation
in mice,31 (2) a duplication at 8q24.3 of ZNF251 and
ZNF517, which have tissue-specific expression highest in604 The American Journal of Human Genetics 93, 595–606, Octoberthe fetal brain and cerebellum,32 and (3) a duplication of
AQP4 (MIM 600308), which encodes the primary water
transporter in brain glial cells, especially in the amyg-
dala and prefrontal cortex, and has been implicated in
epilepsy.33
Because the affected individuals and families had been
analyzed for both de novo CNVs and SNVs, we were able
to develop a model to assess the relative contribution of
each class of genetic variant to autism. First, we confirmed
that inherited CNVs were enriched in the set of probands
without other known de novo CNVs or SNVs (368 in-
herited CNVs in probands versus 327 CNVs in siblings of
336 quads; p < 0.03, two-tailed paired t test). Second, we
developed a logistic regression model, in which the binary
outcome of either probands or siblings was predicted by
the count of disruptive de novo SNVs, de novo CNVs,
and our rare transmitted CNVs. We performed regressions
on both the set of all 411 quads and the set of 276 proband-
sibling pairs with SRS-discordant scores. The results
(Figure 5 and Table S12) revealed a strong effect for disrup-
tive (nonsense, splice, and frameshift) de novo SNVs (OR¼
4.30, p < 0.001) and CNVs (OR ¼ 6.65, p < 0.02) and also
confirmed a statistically independent effect for transmitted
CNVs (OR¼ 1.16, p< 0.04); again, in this model, the effect
was primarily driven by SRS-discordant quads. Although
the strength of de novo SNVs strongly outweighed the
pathogenic effect of inherited CNVs, our model predicted
that the inherited CNV would contribute significantly to
sporadic disease, especially in the case of SRS-discordant
pairs (where the OR increased to 1.26, p < 0.015). We did
not find any significant interactions between our predic-
tors, reflecting the relative infrequency of co-occurring
CNVs and de novo SNVs but also the limited sample size.
It is also possible that careful consideration of rare and
disruptive inherited SNVs could statistically interact with
other classes of mutation, but we did not take these into
account in building our model. Our model suggests that
disruptive de novo SNVs and both inherited and de novo
CNVs contribute independently to the risk of autism. We
believe that future studies of ASD and other complex3, 2013
neurological disorders will contribute significantly to the
understanding of the genetic underpinnings of disease,
especially if an integrated approach considering all disrup-
tive mutations—inherited and de novo, CNV and SNV,
small and large—is applied.Supplemental Data
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